• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Slides for the February 3, 2009 Meeting of the Cardiovascular and Renal Drugs Advisory Committee

Ellis F. Unger, M.D., Deputy Director, Division of Cardiovascular and Renal Products, Office of Drug Evaluation-I, Office of New Drugs, CDER, FDA [PDF]


Eli Lilly and Company Presentation and Backup Files [PDF

Open Public Hearing